Par Pharmaceuticals is to distribute Spectrum’s three abbreviated new drug applications, already approved by the FDA and nine more pending approval. The deal includes other abbreviated new drug applications, currently under development. Par and Spectrum will share profits from the sale of the generic drugs. Par Pharmaceuticals will provide further financial and legal support for the ongoing lawsuits against Spectrum for sumatriptan injection, originally developed by GlaxoSmithKline.